SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a year-on-year increase of 6.93%. Regarding R&D investment, the Company firmly implemented its innovation transformation strategy. During the reporting period, the R&D expenditure increased to RMB 897 million, increased by 1.59% YoY. While increasing the R&D intensity, the Company maintained a positive growth trend in profit. Net profit attributable to shareholders of the list company after deducting extraordinary gain or loss was RMB 501 million, up 21.96% year-on-year. Net profit attributable to shareholders of the listed company was RMB 871 million, increased by 13.87% YoY. Net cash flows generated from operating activities was RMB 1,149 million, up 8.8% YoY.

In the first quarter of 2026, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma firmly continued to advance its innovation transformation, promoted the deep synergy between innovation and R&D and global operations, and further enhanced the foundation for high-quality development. Driven by the continuous increase in R&D investment, the Company's transformation of innovative achievements continues to materialize. During the reporting period, the NDA for 4 Innovative Drugs were accepted by the NMPA or the U.S. FDA, and 14 clinical trials for Innovative Drugs (calculated by approval) were approved by domestic and overseas regulatory authorities, covering core therapeutic areas such as oncology. In the Pharma R&D Annual Review 2026 white paper released by the world-known consulting firm Citeline, Fosun Pharma ranked among the global top 20, gained international professional recognition for its innovative R&D strength and pipeline quality.

Deepening Core Technology Platforms to Consolidate Advantages in Oncology and Other Fields

Fosun Pharma has established an open-ended R&D system that combines in-house R&D, co-development, licensing, fund incubation, and industrial investment, also focused on strengthening core technology platforms such as antibodies/ADC, small molecules, and cell therapy, continuously consolidating its innovation moat in core therapeutic areas including oncology.

In the field of antibody/ADC technology platform, Shanghai Henlius, a subsidiary of Fosun Pharma, has steadily advanced the approvals and clinical progress of several self-developed biological drugs. Notably, denosumab injection (HLX14) secured approval in Canada in March 2026, covering all indications of the reference product approved locally, achieving a global commercialization breakthrough in areas such as osteoporosis, bone metastasis from tumors, and giant cell tumor of bone. The NDA for bevacizumab injection (HLX04) was accepted in the U.S., marking a new milestone in the Company's international registration capabilities for biosimilars. HLX43, an antibody-drug conjugate targeting PD-L1, is expected to create synergy with HLX07 or serplulimab injection for the treatment of advanced colorectal cancer and other solid tumors. HLX3901, a tetraspecific antibody of DLL3×DLL3×CD3×CD28, received approval for clinical trial, demonstrating significant potential in refractory solid tumors through multi-target synergistic activation of immune cells.

In the field of small molecule innovative drug platform, in January 2026, the NDA for foritinib succinate capsules (SAF-189), Fosun Pharma's Class 1 innovative drug, was accepted by the NMPA, intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), expected to provide a new option for precision treatment of lung cancer. In February 2026, the NDA for the self-developed MEK 1/2 inhibitor luvometinib tablets (Trade name in Chinese mainland: Fu Mai Ning⁾ for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) have been accepted and granted in the priority review by the NMPA. This marks a critical step toward full-age coverage following its approval for pediatric and adolescent NF1 patients in May 2025, also brings new hope to a large number of adult NF1 patients in China who lack effective drug treatments. Additionally, the NDA for methoxyetomidate hydrochloride injection (ET-26), a Class 1 innovative drug self-developed by the subsidiary Avanc Pharma for anesthesia induction and short-term surgical anesthesia, was also accepted.

In the field of prospective layout of early-stage pipeline, several new molecules have been approved for the clinical trials: FXB0871, a PD-1-targeted IL-2 fusion protein, was approved for clinical trials in locally advanced or metastatic solid tumors. Based on the ATTENUKINE™ platform, FXB0871 is expected to achieve high efficacy and low toxicity. FXS0683, a next-generation Bcl-2 inhibitor, was approved for Phase I clinical trials in hematological malignancies. Innovative molecule including HLX97 (a KAT6A/B small molecule inhibitor) and HLX3901 (tetra specific antibody of DLL3×DLL3×CD3×CD28) were approved for clinical trials, widely covering refractory solid tumors such as breast cancer and small cell lung cancer. Meanwhile, HLX22 (anti-HER2 monoclonal antibody) entered phase II clinical trials for the first-line treatment of HER2-positive recurrent or metastatic breast cancer in combination with HLX87. HLX43 (PD-L1 ADC) in combination with HLX07 or serplulimab injection, and HLX701 (CD47 fusion protein), among others, have entered Phase I clinical trials, further enhancing the Company's layout in the fields of tumor immunology and targeted therapy.

Expanding Global Commercialization Network and Enhancing Academic Influence

During the reporting period, Fosun Pharma's global registration and commercialization network continued to expand. The overseas registration of products like denosumab and bevacizumab progressed steadily. The Company reached deep collaborations with global partners such as Eisai and Abbott to accelerate the market coverage of innovative products in Japan, Asia-Pacific, Middle East, Africa, and Eastern Europe.

In the academic field, several innovation achievements were presented at top international conferences such as AACR and ASCO. The Phase III study data of luvometinib tablets for adult patients with neurofibromas type 1 (NF1) with symptomatic, inoperable plexiform neurofibromas (PN) was selected for a rapid oral abstract session at 2026 ASCO, the study results will be released for the first time during the meeting. At the 2026 AACR Annual Meeting, Shanghai Henlius, a Fosun Pharma's subsidiary, presented preclinical data for the novel trispecific T-cell engager HLX3902 and the tetraspecific antibody HLX3901, demonstrating best-in-class treatment potential, building a solid foundation for the future clinical development.

AI Embracement: Driving Digital Transformation via FoSTRAID

Fosun Pharma continues to deepen its digitalization and AI strategic layout, and systematically advances the platformisation, engineering and scaled implementation of AI capabilities focusing on core aspects such as new drug R&D, clinical research, products and services, and operation management. On this basis, the fully AI- embracing strategy centered on FoSTRAID (Fosun Pharma Strategic Transformation via AI & Data science) was further defined and steadily advanced. By integrating resources, a digital-intelligence architecture that promotes synergistic development across "foundation — platform — data — agent — scenario — mechanism" has been established.

The self-developed PharmAID^® Pharmaceutical Intelligence Platform deeply applies large language models, fine-tuned with professional medical corpora and R&D data. It integrates full-cycle of decision-making tools including competitor analysis, clinical competitive performance evaluation, NDA approval prediction, and peak sales estimation, comprehensively applied in key scenarios such as target discovery, molecular optimization, clinical writing, intelligence retrieval, and literature interpretation, providing systematic and data-driven support for drug R&D decision-making.

Looking ahead, Fosun Pharma will continue to adhere to the dual drivers of innovation and globalization, deepen its core technology platforms, promote the implementation of AI strategy and accelerate the transformation of its pipeline and global market access. The Company remains committed to providing high-quality healthcare products and services to patients worldwide, striving to become a leading global healthcare innovation integrator.

- END -

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/

香港2026年4月28日 /美通社/ -- 復星國際有限公司（香港聯交所股份代號：00656，簡稱「復星國際」）及其附屬公司（統稱「復星」或「集團」）發佈2025年環境、社會及管治（簡稱ESG）報告。面對愈發嚴峻的全球氣候變化挑戰，復星對標香港聯交所《主板上市規則》附錄C2「環境、社會及管治報告守則」D部分（「新氣候規定」），並參考氣候變化相關財務信息披露工作組（TCFD）建議框架及《國際財務報告準則S2號—氣候相關披露》（「IFRS S2」）發佈了第四份氣候信息披露報告。

作為植根中國、佈局全球的產業集團，復星始終將可持續發展置於戰略核心，以務實行動回應時代與社會的期望。復星的可持續發展戰略為「創造影響力」（Create IMPACT），緊扣六大長期戰略方向，即：I: Innovation-driven 創新驅動、M: Mindful Operation 責任運營、P: People and Partner Oriented 以人為本、A: Advanced Governance精益治理、C: Climate and Planet Positive 綠色發展、T: Transparency透明真實。

積極推動全球可持續發展，ESG評級屢獲佳績

復星以「創新」與「全球化」為引擎，積極深化ESG與商業融合，加速低碳轉型、拓展責任投資、強化社會實踐，以「全球資源嫁接中國能力」，在超過40個國家和地區負責任運營，為全球可持續發展貢獻復星力量。作為負責任的全球公民，復星於2014年正式加入聯合國全球契約組織，全力支持聯合國全球契約組織在人權、勞工、環境及反腐敗等領域的十項原則，並將這些原則與「創造影響力」的可持續發展戰略及行動準則深度融合。

過去一年，儘管全球環境、社會與經濟充滿不確定性，復星仍堅定履行對可持續發展的長期承諾，並收獲佳績。根據最新MSCI 5.0版標準的ESG評級，復星國際MSCI ESG評級榮升AAA，恒生可持續發展評級保持AA-，入選標普全球《可持續發展年鑑2026》並連續位列中國最佳1%；富時羅素ESG評分升至4.2分，並連續第五次入選FTSE4Good成份股。

積極應對氣候變化，推動低碳轉型

面對氣候變化與低碳轉型的趨勢，復星積極響應國家「雙碳」目標，推動碳中和與節能減排，於2021年向社會做出承諾：「力爭於2028年實現碳達峰、2050年實現碳中和」，通過制訂氣候變化緩解和適應策略，支持《巴黎協定》的1.5℃控溫目標。復星更在2050碳中和承諾的基礎上，提出以2024年為基準年，至2034年範圍1和範圍2的溫室氣體排放強度下降20%的中期目標，這是復星對運營排放的嚴格約束，也彰顯集團推動低碳轉型的決心與行動力。

在綠色金融方面，復星持續運用可持續發展掛鈎融資工具拓展低碳與可持續轉型資金來源。2025年，集團完成到期銀團貸款再融資，並籌組首批規模達6.75億美元等值的三年期可持續發展掛鈎銀團貸款，延續綠鞋機制吸引新增銀行參與，最終於2025年9月簽約時總規模增至9.1億美元等值，創公司近五年離岸銀團貸款規模新高，並刷新2025年以來離岸市場民營企業同類貸款規模紀錄，體現資本市場對復星國際可持續發展與融資結構優化方向的認可。

集團積極推動成員企業開展氣候行動。集團在上海的主要辦公場所—上海地標性建築外灘金融中心（BFC）在規劃初期即引入並遵循被譽為綠色建築界的「奧斯卡」LEED 標準，建造初期獲 LEED 金級認證，並於 2022 年以全球最高分榮獲 LEED 鉑金級認證。2025 年，Club Med旗下97%符合條件的度假村通過審核並獲得全球可持續旅遊權威標準—Green Globe 認證；三亞亞特蘭蒂斯、太倉阿爾卑斯國際度假區及麗江地中海國際度假區獲 LEED 金級認證等，展現復星在綠色建築與可持續旅遊領域的持續努力與成果。

復星葡萄牙保險Fidelidade在COP29宣佈成立氣候變化影響研究中心（ICCC），推動氣候風險管理創新，並在COP30展示階段性成果。成立一年以來，ICCC在森林火災風險建模方面取得突破，並開發洪水災害模型工具和預警系統，助力防災政策與社區韌性提升。同期，公司推出創新投資項目—葡萄牙森林基金（Florestas de Portugal），通過森林管理、碳捕捉和土地治理探索兼顧經濟回報與環境效益的可持續投資模式，成為保險業以金融力量參與生物多樣性保護與氣候行動的典範。

2025年，復星繼續以低碳技術打造豫園燈會，踐行碳中和理念，讓東方生活美學與可持續理念交融。依託復星全球平台，豫園燈會已走出國門，先後落地法國巴黎、越南河內、泰國曼谷，成為中外文化交流的重要載體，持續向世界講述「中國故事」，傳遞可持續生活的美好願景。

創新驅動，為患者帶來治癒希望

復星堅持創新驅動，秉持為更多患者帶來治癒希望的初心。旗下健康產業圍繞未被滿足的臨床需求，深度佈局腫瘤、免疫炎症、神經退行性疾病等核心治療領域，積極拓展慢病及罕見病等領域，打造具有長期競爭力的產品管線與綜合解決方案。同時，持續夯實抗體、ADC、小分子、細胞治療等核心技術平台，並拓展核藥、小核酸等前沿技術。

其中，漢斯狀、HLX43、HLX22等上市及在研創新藥實現多項「全球首個」突破。漢斯狀®成為全球首個一線治療廣泛期小細胞肺癌的PD-1單抗，已在40餘國家和地區上市；HLX43在非小細胞肺癌、婦科腫瘤、食管鱗癌等多個領域展現「高效、低毒」優勢；HLX22則是全球首款同時獲歐盟與美國孤兒藥資格認定的胃癌抗HER2靶向療法。

此外，復星醫藥持續助力非洲社區健康發展。截至2025年12月底，復星醫藥自主研發的注射用青蒿琥酯累計救治全球超8,800萬重症瘧疾患者，已向全球累計供應超過4.4億支注射用青蒿琥酯。

商業向善，積極回饋社會

「商業向善」是復星不變的承諾。為更好地推動企業社會責任的履行和實施，復星基金會於2012年成立，在全球應急馳援、鄉村振興、健康、教育、文化藝術及青少年發展等領域不懈努力，創造社會價值。復星基金會持續推進鄉村醫生項目，自2017年啓動的鄉村醫生項目，已覆蓋16個省、市、自治區的78個項目縣，累計守護2.5萬名鄉村醫生，惠及300萬戶農村家庭，並將「AI村醫助手」帶入基層，提升醫療服務覆蓋面與效率。

自上而下的ESG改進長效機制，ESG表現與董事會績效掛鈎

復星建立了自上而下的ESG提升長效機制，將ESG管理績效納入執行董事績效評估體系，亦將ESG管理績效考核制度覆蓋範圍延伸至本集團CEO及各業務集團負責人。復星在董事會下設立ESG董事委員會，協助董事會指導及監察集團發展及落實ESG工作。在管理及決策層面，復星在管理層設立ESG決策委員會，對ESG戰略落地提供決策支持。在執行層面，集團亦成立了ESG管理委員會及ESG工作小組，確保設立合適及有效的ESG風險管理及內部監控系統，全面落實復星國際的ESG策略及相關行動。

展望未來，復星將繼續聚焦主業、堅持創新和全球化發展。同時，公司將持續關注全球可持續發展趨勢，不斷完善ESG管理體系，積極響應國家戰略，保障信息安全，落實「雙碳」目標，參與公益慈善，保障員工權益，借助復星全球產業生態的資源與優勢，在可持續發展領域創造更大影響力，持續為世界創造美好。

了解復星ESG的更多詳情，請參閱復星國際2025年ESG報告：
香港聯交所披露易網站（https://www.hkexnews.hk/index_c.htm）
或本公司ESG網站（https://www.fosun.com/esg/）
復星國際2025年氣候信息披露報告電子版本發佈於本公司ESG網站：
（https://www.fosun.com/esg/）

關於復星
復星創立於1992年，經過逾30年發展，已成為一家創新驅動的全球家庭消費產業集團。秉持讓全球家庭生活更幸福的使命，復星致力於服務全球家庭客戶，戰略聚焦健康、快樂、富足的幸福生態系統。2007年復星國際在香港聯交所主板上市（股份代號：00656.HK），截至2025年12月31日，公司總資產達人民幣7,162億元，最新MSCI ESG評級為AAA。

NINGDE, China, April 28, 2026 /PRNewswire/ -- On April 27, CATL and HyperStrong signed a strategic cooperation agreement on sodium-ion batteries for energy storage in Ningde, Fujian. The two parties announced a three-year partnership covering 60GWh of sodium-ion battery supply, marking a significant milestone for the industrialization of sodium-ion batteries technology.

As CATL's first strategic partner for sodium-ion energy storage, HyperStrong will work closely with CATL in areas including technology R&D, product applications, and project deployment.

This partnership marks CATL's successful breakthrough across the entire value chain for mass production of sodium-ion batteries, giving the company the capacity for large-scale delivery. It also represents the largest sodium-ion battery supply agreement in the world to date, ushering in a new phase of large-scale expansion for the global sodium-ion battery industry.

Through morphology control and surface modification, CATL has significantly enhanced the energy density of sodium-ion batteries. On the manufacturing side, the Company has systematically addressed key process challenges in mass production—such as foaming in hard carbon production lines and moisture control—by leveraging core technologies including angstrom-level pore size regulation, surface molecular water-locking, and adaptive dynamic formation, thereby ensuring consistency across large-volume production.

Sodium-ion batteries offer excellent adaptability across a wide temperature range, deliver outstanding high-temperature cycle life, generate less heat during operation, and experience lower cell expansion stress, resulting in superior safety and stability. In long-duration energy storage applications, system integration can be effectively simplified, reducing auxiliary energy losses and comprehensively improving overall plant efficiency and economic performance.

In addition, CATL's sodium-ion energy storage batteries feature a platform-based design with the same form factor as lithium-ion batteries, ensuring high compatibility with the existing industrial chain. This effectively reduce adaptation costs and significantly shortens the timeline from product readiness to power station deployment.

The 60GWh sodium-ion battery cooperation marks a major milestone for both parties. As sodium-ion technology enters a phase of large-scale development, the two sides will continue to deepen collaboration, promote high-quality growth of the energy storage industry, and provide more resilient and diversified technological support for the global energy transition.

HONG KONG, April 28, 2026 /PRNewswire/ -- CNOOC Limited ("the Company", SEHK: 00883 (HKD counter) and 80883 (RMB counter), SSE: 600938) today announced its operating results for the first quarter of 2026. The Company continued to increase reserve and production, while pursue effective cost control and efficiency enhancement. Net production of oil and gas and net profit attributable to equity shareholders both grew strongly.

In the first quarter of 2026, CNOOC Limited achieved a net production of 205.1 million barrels of oil equivalent (BOE), representing an increase of 8.6% year-on-year (YoY), reaching a new record high. Net production from China grew by 7.0% YoY to 140.0 million BOE. Overseas net production rose by 12.3% YoY to 65.1 million BOE. The growth was mainly attributable to the production contribution from oil and gas fields including Kenli 10-2 and the Yellowtail Project in Guyana.

During the period, the Company made 4 new discoveries and successfully appraised 12 oil and gas-bearing structures. Among them, the new discovery of Luda 16-1 demonstrated the exploration prospects of Paleogene lithological play in the Liaozhong depression. Enping 20-5 was successfully appraised, showing remarkable results of integrated rolling exploration. In terms of development and production, the Huizhou 25-8 Oilfield Comprehensive Adjustment Project and the Penglai 19-3 Oilfield 1/2/3/8/9 Block Secondary Adjustment Project have successfully commenced production, while other new projects progressed smoothly.

Driven by higher realized oil prices and increased oil and gas sales, the Company's unaudited oil and gas sales revenue for the quarter reached approximately RMB97 billion, representing an increase of 9.9% YoY. Net profit attributable to equity shareholders of the Company was RMB39.14 billion, an increase of 7.1%YoY. The all-in cost was US$28.41 per BOE, maintaining cost competitiveness. During the period, the Company's capital expenditures amounted to approximately RMB33.02 billion, which was mainly due to the accelerated deployment of exploration and adjustment wells, as well as the ramp-up of production capacity construction.

Mr. Huang Yongzhang, Chief Executive Officer and President of the Company, said, "In the first quarter, CNOOC Limited made a good start for the year with tangible achievements in reserve and production growth and quality and efficiency enhancement. We will step up efforts in oil and gas exploration and development, coordinate technological breakthroughs, and focus on lean management to ensure the high-quality completion of all tasks."

— End —

Notes to Editors:

More information about the Company is available at https://www.cnoocltd.com.

*** *** *** ***

This press release includes forward-looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company's expectations, as a result of salient factors including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environment policies, the Company's price forecast, mergers, acquisitions and divestments activities, "health, safety, security and environment" (HSSE) and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Liu Cui
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: [email protected] 

Cheng Yao
Ever Bloom (HK) Communications Consultants Group Limited
Tel: +852 5540 0725
Fax: +852 2111 1103
E-mail: [email protected] 

HONG KONG, April 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the officially updated 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (NSCLC). These strong recommendations further solidify ivonescimab's breakthrough clinical value and its position as a new standard of care (SOC), highlighting its leadership as a next-generation immunotherapy driving the IO 2.0 era.

Key Highlights

In the Phase III HARMONi-2 study, ivonescimab monotherapy demonstrated superior progression-free survival compared with pembrolizumab in first-line PD-L1-positive (TPS ≥1%) NSCLC. Based on these results, ivonescimab has been upgraded to a Class I recommendation for first-line treatment of both squamous and non-squamous NSCLC with PD-L1 TPS ≥1%. This indication was previously approved in China and included in the National Reimbursement Drug List (NRDL). The upgrade strengthens its position as a preferred first-line option for PD-L1-positive advanced NSCLC.

In the Phase III HARMONi-6 study, ivonescimab plus chemotherapy showed positive results versus PD-1 inhibitor plus chemotherapy in first-line squamous NSCLC. This combination has received a new Class II recommendation for first-line treatment of squamous NSCLC. The supplemental application for this indication is currently under regulatory review.

Latest CSCO Guideline Recommendations for Ivonescimab

• Post-resistance treatment in EGFR-mutant NSCLC: Ivonescimab plus chemotherapy maintains a Class I recommendation.
• First-line treatment for advanced driver gene-negative squamous NSCLC with PD-L1 TPS ≥1%: Ivonescimab monotherapy upgraded to Class I recommendation.
• First-line treatment for advanced driver gene-negative non-squamous NSCLC with PD-L1 TPS ≥1%: Ivonescimab monotherapy upgraded to Class I recommendation.
• First-line treatment for advanced driver gene-negative squamous NSCLC: Ivonescimab plus chemotherapy newly added as Class II recommendation.

To date, the breakthrough clinical value of ivonescimab has been demonstrated in dozens of clinical trials and real-world experience involving more than 70,000 patients. It has gained wide acceptance among oncologists and patients, contributing to the ongoing advancement of immuno-oncology treatment paradigms globally.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

香港和寧波2026年4月27日 /美通社/ -- 均勝電子（699）公佈2026財年第一季業績。公司積極應對全球汽車產銷量承壓等影響，整體經營韌性進一步提升，期內股東應佔溢利約人民幣4億元，按年升約18.1%，近三年增幅表現續強。公司Q1實現收入逾人民幣138億元；新增訂單額達人民幣275億元，大幅優於舊年同期的157億元。

公司指出，盈利能力提升主要得益於全球資源配置優化，供應鏈本地化適配與差異化成本結構的效益改善，尤其是海外地區持續改善提升趨勢顯著。期內，整體毛利率保持相對穩定，經營活動現金流淨額約人民幣9.1億元，按年升約5.5%，經營質量持續提升。

報告顯示，均勝電子單季新獲全球訂單全生命週期總金額約人民幣275億元。尤其是，公司相繼獲得國內某自主品牌及某合資品牌智能駕駛解決方案項目，並取得國內頭部新勢力品牌出海車型的智能座艙業務定點。隨著高階智能化產品的滲透率提升，多個高品質訂單下半年逐步投產，智駕業務將成為新增長引擎之一。

期內，均勝電子研發費用約人民幣8.4億元。公司表示，將繼續重點圍繞智能駕駛等智能電動汽車行業前沿技術、新興智能體、伺服器電源等領域加大研發投入，並推進重要客戶訂單落地。

智能駕駛領域，公司以「多晶片平台+生態合作」為技術路線，實現「艙、網、駕」和AI中央計算的深度融合。目前，公司已與高通、輝達、地平線、黑芝麻智能等晶片商，以及Momenta、斯年智駕等算法公司合作，持續迭代L3/L4高級輔助駕駛功能。另外，均勝電子近日基於英特爾高性能晶片平台，打造新一代AI智娛中心，賦能艙駕AI全模態交互新體驗。

同期，均勝電子新興智能體「大小腦、肢體和能源管理」領域研發提速。第一季，均勝與恩力動力達成戰略合作，加速新興智能體半固態/固態電池技術攻關。公司還投資靈巧手公司「臨界點」，同期還成立均勝靈犀智能科技，劍指新興智能體靈巧手，進一步豐富部件矩陣，以築實新興智能體部件龍頭地位。

新業務進展方面，均勝電子積極推進車端技術向智算中心基建領域橫向拓展，取得新進展。公司複用車規級電源系統的拓撲、器件及高可靠性，將向市場提供安全可靠、運維方便的伺服器電源整體方案。而且，均勝電子還通過戰略投資新菲光推進光模塊的業務佈局和應用落地，面向全球市場拓展新業務機會。

關於均勝電子

均勝電子（600699.SH / 699.HK）是全球領先的智能科技解決方案提供商，專注於汽車電子、汽車安全及新興智能體關鍵部件的研發與製造。公司全球設有超過 25 個研發中心和 60 個生產基地，客戶覆蓋超 100 個全球汽車品牌。2025年營業收入達人民幣 612 億元。

均勝電子定位「汽車 + 新興智能體Tier1」，向客戶提供智能駕駛、智能座艙、智能網聯、新能源管理、汽車安全以及新興智能體關鍵部件領域的創新產品。公司是全球智能駕駛頭部供應商，其全棧解決方案可支持實現 L2 到 L4 級別的多場景自動駕駛功能；公司也是中國第二、全球第四大智能座艙域控系統供應商。此外，均勝電子亦已向國內外知名新興智能體公司送樣或供貨，是全球新興智能體部件行業的領先者。

HONG KONG and NINGBO, China, April 27, 2026 /PRNewswire/ -- Joyson Electronics (699.HK) announced financial results for Q1 2026 on April 27. Revenue for the period reached approximately RMB 13.8 billion, profit attributable to shareholders was approximately RMB 400 million, up around 18.1% YoY. Fresh orders reached RMB 27.5 billion, significantly outperforming RMB 15.7 billion in the same period last year.

Joyson noted that the improvement in profitability was primarily driven by optimized global resource allocation and ongoing gains from supply chain localization, alongside benefits from a more differentiated cost structure. These initiatives have supported a multi-quarter uptrend in overall margins.

During the period, the overall gross margin remains relatively stable year-on-year. Net cash generated from operating activities was approximately RMB 910 million, up about 5.5% year-on-year, reflecting continued improvement in operating quality.

According to the report, Joyson Electronics booked new global orders with a total life‑cycle value of about RMB 27.5 billion in Q1 2026. The Company won intelligent driving solution projects from a Chinese brand and a joint‑venture brand and achieved a smart cockpit nomination for the overseas lineup of a leading new automotive force.

With advanced intelligent products gaining penetration, and several high‑quality orders entering production in 2H 2026, intelligent driving is expected to emerge as a new growth engine.

During this quarter, R&D expenses amounted to approximately RMB 839 million. Joyson said it will continue to step up R&D investment, with a focus on frontier technologies for intelligent electrified vehicles—such as autonomous driving—as well as next-generation agents, and server power solutions, while accelerating the conversion and rollout of orders from key customers.

Guided by its "multi-chip platform + ecosystem collaboration" technology roadmap, Joyson Electronics is advancing deep integration across cockpit, connectivity and driving functions, as well as central computing. Joyson has established partnerships with leading chipmakers including Qualcomm, NVIDIA, Horizon Robotics and Black Sesame, as well as algorithm companies such as Momenta and Senior Smart Driving, to continuously iterate L3/L4 advanced driver-assistance capabilities.

Recently, based on Intel's high-performance chip platform, Joyson Electronics developed a next-generation AI infotainment hub to enable an upgraded, full-modality cockpit-and-driving AI interaction experience.

In parallel, the company has accelerated R&D in next-generation agents across "brain, motion control and energy management." Recently, Joyson Electronics partnered with Beijing Enpower to speed up R&D breakthroughs in solid-state battery technologies for next-generation agents.

Earlier, Joyson Electronics also invested in the dexterous-hand company AGILINK and established Joyson Lingxi Intelligent Technology, targeting dexterous-hand development. These initiatives further enrich the company's components portfolio of next-generation agents and strengthen its positioning as a leading components provider.

In addition, Joyson Electronics is actively extending its in-vehicle technologies horizontally into artificial intelligence computing center and has made further progress. Leveraging the topology, key components, and high reliability of its automotive-grade power systems, it plans to offer safe, reliable and easy-to-maintain integrated server power solutions soon.

Furthermore, Joyson Electronics has made a strategic investment in an optical module company with manufacturing capacity in North America. And they will jointly advance global deployment of optical modules, expanding new business opportunities worldwide.

About Joyson Electronics

Joyson Electronics (600699.SH / 699.HK) is a leading global provider of smart technology solutions, specializing in the R&D and manufacturing of automotive electronics, automotive safety systems, and key components for next-generation agents. Joyson operates more than 25 R&D centers and 60 production facilities, and serves over 100 global automotive brands. Revenue reached RMB 61.2 billion in 2025.

Joyson Electronics positions itself as a "Tier 1 supplier for automotive and next-generation agents," providing customers with innovative products in the fields of autonomous driving, intelligent cockpits, car connectivity, E-Mobility, automotive safety, and key components of next-generation agents. It is a leading global supplier of autonomous driving, with its full-stack solutions supporting multi-scenario autonomous driving capabilities from Level 2 to Level 4. Joyson is also the second-largest supplier of intelligent cockpit domain control systems in China and the fourth largest globally.

Additionally, Joyson Electronics has supplied samples or products to companies of next-generation agents worldwide, establishing itself as a leader in the components industry of next-generation agents.

Oil prices hiked to historical new highs, while Iran peace talks stalled and tensions in the Strait of Hormuz escalated again, leading to mixed performance in US equities on Monday.

The S&P 500 and Nasdaq opened lower but closed higher, both setting new closing highs. The S&P 500 ticked up only 8 points or 0.1% to close at 7,173, while the Nasdaq added 50 points or 0.2% to 24,887. The DJIA slid 62 points or 0.1% to 49,167.

It is reported that Qualcomm (QCOM.US) is partnering with OpenAI to develop AI smartphone chips, and is cooperating with MediaTek for production, with mass production expected in 2028. The stock hit its high for the day shortly after the market opened, hyping up 8% but closing up just 1%.

Although the Nasdaq closed lower, individual large-cap stocks posted notable gains. Nvidia (NVDA.US) leaped 4%, while Intel (INTC.US) mounted 3%. Alphabet (GOOG.US) jumped up nearly 2%.

Microsoft (MSFT.US) stabilized. The company will no longer pay revenue share to OpenAI, and its OpenAI license will now become non-exclusive.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, April 27, 2026 /PRNewswire/ -- J&T Global Express Limited ("J&T Express" or "J&T" or "the Company", stock code: 01519), a global logistics service provider, today released its 2025 Environmental, Social and Governance (ESG) Report. The report comprehensively presents the Company's latest practices and achievements in intelligent operations, energy management, employee rights protection, talent development, business ethics management, and social welfare, demonstrating its firm commitment to integrating sustainable development concepts into its global logistics network and continuously promoting high-quality development.

Deepening Green Operations and Continuously Promoting Energy Conservation and Carbon Reduction

Over the past year, J&T Express has continued to advance smart logistics and energy transition, utilizing technologies such as AI and big data throughout the entire process of pickup, sorting, line-haul transportation, and delivery to optimize transportation routes, improve transit and sorting efficiency, and enhance last-mile delivery capabilities. In terms of transit, by the end of 2025, J&T Express had put into operation a total of 14 self-built core logistics parks globally, with a total gross floor area of 1.05 million square meters. In addition, the Company has invested heavily in energy-saving logistics equipment, deploying over 150,000 permanent magnet synchronous motorized rollers and more than 400 energy-saving conveyor belts. In terms of last-mile transportation, J&T Express is accelerating the construction of an autonomous vehicle delivery network, with the number of autonomous vehicles put into operation exceeding 1,000 by the end of 2025, leveraging intelligent algorithms to achieve optimal route planning and improve last-mile delivery efficiency. In terms of green packaging, the cumulative deployment of reusable transit bags globally reached approximately 38.27 million, with cumulative usage reaching approximately 3.33 billion times.

In terms of low-carbon transportation, J&T Express has continuously promoted the use of clean and electric transportation vehicles. In China, the Company had been investing in new LNG tractors in 2025, bringing the total to 1,697, accounting for 30% of the total number of self-owned tractors, with the greenhouse gas emission intensity of self-owned line-haul vehicles decreasing by 6% compared to 2024. The Philippines took the lead in achieving 100% use of B5 biodiesel for vehicle transportation; Singapore introduced electric trucks, accounting for 6% of its total truck fleet. At the same time, the Company promoted the coordinated development of green transportation methods such as railway and maritime transport, further optimizing the transportation structure and improving efficiency.

Strengthening Employee Care and Safeguarding Rights and Growth

J&T Express continues to create an open, inclusive, and equal-opportunity work environment, improving its employee care system around career growth, health management, and employee welfare and care. In China, the 2025 J&T Express Co., Ltd. (Entire Network) Platform Algorithm and Labor Rules Agreement was implemented in Shanghai last July, becoming the first network-wide algorithm negotiation agreement in China's express delivery industry. It covers over 290,000 workers in J&T Express's self-operated and franchise outlets across provinces and regions in Chinese Mainland. Focusing on three major issues: salary protection, career development, and algorithm transparency, it further improves the rights protection mechanism for workers in new forms of employment.

In terms of talent development, J&T Express systematically advanced the construction of a multi-level talent training system around four strategic directions: "building channels, supplying talent, strengthening overseas presence, and solidifying foundations." In 2025, the total number of courses on the digital training and knowledge management platform for global employees increased by 60% year-over-year (YoY), and total training hours increased by 2.8 times YoY. In addition, during the reporting period, the Company organized and participated in various safety training sessions globally over 27,000 times, covering over 1.4 million participants, continuously consolidating its safety culture and employee protection foundation.

Fulfilling Social Responsibilities and Supporting Local Community Development

J&T Express continued to carry out social welfare actions in areas such as rural revitalization, educational public welfare, and post-disaster assistance. In Chongqing, China, the Company introduced drones for the first time to collect and transport navel oranges in mountainous areas, with a single drone providing a daily transport capacity of up to 10,000 kilograms, effectively reducing labor costs for fruit farmers. In Thailand, the Company partnered with the Department of Agricultural Extension to launch fresh fruit logistics services, facilitating the efficient circulation of agricultural products.

In terms of emergency disaster relief, the Company's teams in various countries continued to participate in disaster assistance efforts. Following the fire in Tai Po, Hong Kong, J&T Express swiftly initiated a special donation of HK$10 million and delivered 300 sets of daily necessities to temporary shelters. After the floods in Indonesia, the Company's Indonesian headquarters chartered flights to transport 13 tons of supplies to severely affected areas, supporting the affected population in restoring their livelihoods.

Improving Business Ethics and Building a Solid Global Compliance Bottom Line

In terms of business ethics and compliance management, J&T Express continued to improve its global governance system, which is coordinated by the Group headquarters and executed locally by subsidiaries, covering multiple dimensions such as anti-corruption, fair competition, and supply chain compliance. During the reporting period, the Company conducted special training on anti-money laundering, counter-terrorist financing, and anti-corruption for directors and senior management, achieving a 100% coverage rate. It also carried out integrity education and training, covering over 89,000 participants cumulatively, and extended compliance requirements to the supply chain system, further solidifying the foundation for global operations.

Dylan Tey, Chief Financial Officer of J&T Express, stated: "Within J&T's rapidly developing global logistics network, ESG has evolved from a concept into concrete operational capabilities. Over the past year, we have proactively explored green transportation transformation and the governance of new forms of employment, including advancing diversified low-carbon transportation solutions and establishing one of the industry's first algorithm negotiation mechanisms. These relevant practices have received multiple industry recognitions. Looking ahead, J&T will continue to leverage technology to empower operations and let responsibility drive growth, continuously improving our ESG governance system and the quality of information disclosure to create long-term value for key stakeholders including global customers, employees, and communities."

• Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY
• Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion
• Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion

SHANGHAI, April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first quarter ending March 31, 2026 ("Reporting Period"): 

• Total revenue reached RMB 12.44 billion, up 28.8% YoY; revenue from Continuing Operations up 39.4% YoY.
• Adjusted non-IFRS gross profit margin up 8.5pts YoY to 50.4%.
• Adjusted non-IFRS net profit up 71.7% YoY to RMB 4.60 billion; adjusted non-IFRS net profit margin up 9.2pts YoY to 37.0%; adjusted non-IFRS diluted EPS^[1] up 67.0% YoY to RMB 1.57.
• Net profit^[2] up 26.7% YoY to RMB 4.65 billion; diluted EPS up 23.4% YoY to RMB 1.58.
• Backlog for Continuing Operations reached RMB 59.77 billion as of March 31,2026, up 23.6% YoY, as we continue to focus on our core CRDMO strategy and further enhance business visibility. 
• Adjusted operating cash flow^[3] up 21.7% YoY to RMB 3.69 billion, driven by sustained business growth, enhanced operational efficiency and financial management.
• Sustained and steady business growth driven by our unique, fully integrated CRDMO platform. Guided by "follow the molecule" and "win the molecule" strategies, WuXi Chemistry's small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first quarter of 2026, we added 328 new molecules to the small molecule Development and Manufacturing (D&M) pipeline. As of March 31, 2026, our small molecule D&M pipeline reached 3,550 molecules, representing an increase of 9 projects in phase III and commercial stages in the first quarter of 2026.
• The Company reaffirms its full-year guidance with strong confidence. We are closely monitoring market dynamics and business development, and will raise guidance when appropriate.

Management Comment 

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "In the first quarter, our business segments delivered broad-based momentum, with strong growth in both revenue and profit. Our backlog of RMB 59.8 billion for Continuing Operations reflects the strength of our unique CRDMO business model, efficiently enabling the growing needs of our customers."

"Building on this solid performance and sustained efficient execution, we are fully confident in achieving our 2026 full-year guidance. We are accelerating proactive capacity planning and global capability building, continuously enhancing operational and management resilience, and delivering even greater value for customers and shareholders."

"WuXi AppTec remains committed to our core value of 'doing the right thing and doing it right,' enabling our global partners and realizing our vision that 'every drug can be made and every disease can be treated.'"

Business Performance by Segment

• WuXi Chemistry: Continuous Pipeline Expansion and Steady Late-stage Progression, While Accelerating Proactive Capacity Planning
  • Driven by steady pipeline progression to late stages, and the sequential ramp-up of new capacity throughout last year, Q1 revenue of WuXi Chemistry reached RMB 10.62 billion, up 43.7% YoY.
  • With continued optimization of production processes and improvements in capacity efficiency driven by the growth of late-stage clinical and commercial projects, Q1 adjusted non-IFRS gross profit margin of WuXi Chemistry steadily improved 5.4pts YoY to 52.8%.
  • We are accelerating proactive capacity planning. We plan to initiate the new Changzhou site ahead of schedule to better meet growing customer demand.
  • Small molecule drug discovery service ("R") continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to global customers. Meanwhile, 83 molecules were converted from R to D phase. Guided by our "follow-the-customer" and "follow-the-molecule" strategies, we have built trusted partnerships that underpin the sustainable growth of our CRDMO business.
  • Small molecule D&M service maintains strong momentum.

i. The small molecule CDMO pipeline continued to expand, adding 328 new molecules in the first quarter of 2026. As of March 31, 2026, our pipeline reached 3,550 molecules, including 89 commercial projects, 94 in phase III, 386 in phase II and 2,981 in phase I and pre-clinical stages. Notably, commercial and phase III projects increased by 9 during the first quarter.
ii. With our business model continuously attracting high-quality molecules, and the pipeline steadily advancing to late stages, aligned with proactive capacity planning and strong execution, Q1 revenue of small molecule D&M rose 80.1% YoY to RMB 6.93 billion.

• • TIDES business (oligo and peptides) sustains rapid growth.

i. TIDES Q1 revenue up 6.1% YoY to 2.38 billion, with full-year revenue expected to grow about 40% YoY.
ii. TIDES D&M customers grew 28% YoY, and molecules grew 59% YoY.

• WuXi Testing^[4]: Strengthening Differentiated Capabilities and Operational Management; Drug Safety Evaluation Services Maintained Leading Position
  • WuXi Testing Q1 revenue increased 27.4% YoY to RMB 1.13 billion. Notably, revenue from drug safety evaluation services grew 34.8% YoY, maintaining an industry-leading position in the Asia-Pacific region.
  • Driven by differentiated capabilities and enhanced operational management, WuXi Testing gross profit margin continued to improve sequentially each quarter, with Q1 adjusted non-IFRS gross profit margin up 10.8pts YoY to 35.5%.
  • The Company is committed to actively enabling customers in global licensing deals. New modality business continued its strong momentum, contributing more than 30% of WuXi Testing Q1 revenue, while maintaining its leading position in areas including nucleic acids, conjugates, multispecific antibodies and peptides.
  • The Company continued to drive excellence across R&D and service capabilities, with DMPK steadily advancing new capacity in Qidong and Shanghai to efficiently respond to growing and diversified customer demand.

• WuXi Biology: Continues to Follow the Science & Generate Downstream Opportunities; In Vivo & In Vitro Synergies and New Modalities Drove Growth  
  • WuXi Biology builds differentiated drug discovery capabilities in emerging therapeutic areas. It actively expands global business and efficiently generates downstream opportunities for the CRDMO model by continuously contributing more than 20% of the Company's new customers.
  • We efficiently enable our global customers through integrated in vitro & in vivo drug discovery capabilities, cross-regional collaboration and end-to-end solutions in emerging areas. Q1 revenue of WuXi Biology reached RMB 0.67 billion, up 10.1% YoY.
  • With continuous business integration and enhanced operational efficiency, WuXi Biology Q1 adjusted non-IFRS gross profit margin increased 0.4pts YoY to 36.7%. WuXi Biology closely follows the market and maintains a dynamic pricing strategy, maximizing its value in generating downstream opportunities.
  • We achieved rapid revenue growth driven by accelerated progress in integrated in vitro screening and enhanced in vivo pharmacology capabilities. Non-oncology business maintained a competitive edge, serving as a key growth contributor.
  • New modality business continued to drive growth, contributing more than 30% of WuXi Biology Q1 revenue, supported by rapid new customer expansion in areas including nucleic acids, antibody conjugates and peptides.

This release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For additional information, please refer to the WuXi AppTec 2026 First Quarterly Results Presentation and 2026 First Quarterly Report disclosed on the Company's official website, as well as the Company's disclosure documents and information on the websites of Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

Net profit attributable to the owners of the Company ("Net Profit") is prepared in accordance with China Accounting Standards for Business Enterprises ("CAS"), in currency of RMB. All other financial information disclosed in this press release is prepared in accordance with the International Financial Reporting Standards Accounting Standards ("IFRS"), in currency of RMB.

The 2026 First Quarterly Report of the Company has not been audited.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

Forward-Looking Statements

This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends", or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients' intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor an undertaking by WuXi AppTec Co., Ltd. ("WuXi AppTec" or the "Company") to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law.

Continuing Operations and Discontinued Operations

In accordance with IFRS, the Company has classified operations with signed equity sale agreements, completed sales, or those being discontinued during the reporting period or comparative periods as discontinued operations ("Discontinued Operations"). Comparative disclosures have been adjusted accordingly. The remaining operations of the Company will continue to be reported as continuing operations ("Continuing Operations").

Use of Adjusted Non-IFRS Financial Measures

To supplement the Company's IFRS consolidated financial statements, we also provide adjusted non-IFRS gross profit, adjusted non-IFRS net profit attributable to the owners of the Company ("Adjusted Non-IFRS Net Profit), adjusted non-IFRS diluted earnings per share ("Adjusted Non-IFRS Diluted EPS") and adjusted operating cash flow. These measures are not required by, or presented in accordance with IFRS.

We believe that the adjusted non-IFRS financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. The management of the Company believes such adjusted non-IFRS financial measures is widely accepted and adopted in the industry the Company operates. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation, or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.